Effect of thymalin on adaptive immunity in complex therapy for patients with COVID-19-Reference-Cited by-同舟云学术

Effect of thymalin on adaptive immunity in complex therapy for patients with COVID-19

Published:2021-02-07 Issue:8 Volume:98 Page:593-599
ISSN:2412-1339
Container-title:Clinical Medicine (Russian Journal)
language:
Short-container-title:jour

Author:

Khavinson V. Kh.¹^ORCID,Kuznik B. I.²^ORCID,Volchkov V. A.³^ORCID,Rukavishnikova S. A.⁴^ORCID,Titova O. N.⁵^ORCID,Akhmedov T. A.⁴^ORCID,Trofimova S. V.⁶^ORCID,Ryzhak G. A.⁶^ORCID,Potyomkin V. V.⁴^ORCID,Saginbaev U. R.⁵^ORCID

Affiliation:

1. Saint Petersburg Institute of Bioregulation and Gerontology; I.P. Pavlov Institute of Physiology of the Russian Academy of Sciences

2. Chita State Medical Academy

3. Saint Petersburg City Multiprofile Hhospital №2

4. Saint Petersburg City Multiprofile Hhospital №2; Saint Petersburg State I.P. Pavlov Medical University

5. Saint Petersburg State I.P. Pavlov Medical University

6. Saint Petersburg Institute of Bioregulation and Gerontology

Abstract

Results of comparative assessment of level of antibodies of IgG to SARS-CoV-2 in dynamics at standard and complex methods of treatment with use of medicinal peptide medicine of a timus of a timalin for patients with COVID-19 are presented in article. It was found that as a result of standard treatment, patients showed a decrease in antibody levels by 53% after 104 days. The addition of thymalin to standard therapy slowed down the decline of this indicator. So, a similar indicator in patients who took thymalin was only 21%. This contributed to maintaining strained adaptive immunity. The detected immunomodulatory properties of the preparation of thymalin with respect to COVID-19 can be reflected both in the formation of an effective immune layer of the population through natural immunization, and in the process of antibody formation during vaccination of target contingents.

Publisher

Medical Informational Agency Publishers

Subject

General Medicine

Reference16 articles.

1. Rokni M., Ghasemi V., Tavakoli Z. Immune responses and pathogenesis of SARS-CoV-2 during an outbreak in Iran: Comparison with SARS and MERS. Rev. Med. Virol. 2020;30(3):e2107. DOI: 10.1002/rmv.2107

2. Leung D.T., Tam F.C., Ma C.H., Chan P.K., Cheung J.L.K., Niu H. et al. Antibody response of patients with severe acute respiratory syndrome (SARS) targets the viral nucleocapsid. J Infect. Dis. 2004;190(2):379–86. DOI: 10.1086/422040

3. Tan Y., Liu F., Xu X., Ling Y., Huang W., Zhu Z. et al. Durability of neutralizing antibodies and T-cell response post SARS-CoV-2 infection. Front. Med. 2020;14:746–751. DOI: 10.1007/s11684-020-0822-5

4. Wu F., Wang A., Liu M., Wang Q., Chen J., Xia S. et al. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered 2 patient cohort and their implications. medRxiv. 2020. DOI: 10.1101/2020.03.30.20047365

5. Yiğenoğlu T.N., Hacıbekiroğlu T., Berber İ., Dal M.S., Baştürk A., Namdaroğlu S. et al. Convalescent plasma therapy in patients with COVID-19. J. Clin. Apher. 2020;35(4):367–373. DOI: 10.1002/jca.21806

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Main scientific achievements of the academician of the RAS Vladimir Kh. Khavinson: peptides and aging;Medical academic journal;2024-09-11